Alembic Pharmaceuticals Ltd (APLLTD)
₹797.85
Mkt cap
₹15,624 Cr
P/E ratio
20.90
P/B
2.76
Div yield
1.51%
ROE
13.40%
ROCE
12.60%
EPS (TTM)
₹38.17
Book value
₹289
52W range
636–998
Sector
Healthcare
Price history
Previous close
Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company has 3 R&D and 5 manufacturing facilities.
NSE APLLTDBSE 533573
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−20.06% from high₹798
₹636+25.49% from low₹998
Current
₹797.85
Prev close
₹794.85
Day
+0.38%
Price performance
1D
+0.48%
1W
+5.07%
1M
−7.30%
3M
−0.51%
6M
+4.93%
1Y
−13.34%
YTD
−4.45%
Financials
Revenue, profit & margin
P/E ratio
20.9×
APLLTD is 39% below the sector median of 34.5×
APLLTD20.9×
Sector median34.5×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,486 | 1,595 | 1,631 | 1,517 | 1,562 | 1,648 | 1,693 | 1,770 | 1,711 | 1,910 | 1,876 | 1,848 | 2,150 | |
| Expenses | 1,287 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 | 1,430 | 1,594 | 1,585 | 1,620 | 1,818 | |
| Operating Profit | 199 | 208 | 266 | 260 | 237 | 239 | 260 | 271 | 281 | 316 | 292 | 228 | 332 | |
| OPM % | 13% | 13% | 16% | 17% | 15% | 15% | 15% | 15% | 16% | 17% | 16% | 12% | 15% | |
| Other Income | 12 | 10 | 3 | 4 | 2 | 30 | 10 | 14 | 6 | 8 | -27 | 2 | 15 | |
| Interest | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 | 24 | 24 | 23 | 23 | 28 | |
| Depreciation | 66 | 68 | 69 | 69 | 69 | 71 | 70 | 69 | 74 | 76 | 80 | 89 | 98 | |
| Profit before tax | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 | 190 | 224 | 162 | 119 | 222 | |
| Tax % | 7% | -1% | 2% | 3% | 14% | 15% | 23% | 18% | 19% | 18% | 18% | -70% | 22% | |
| Net Profit | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 | 154 | 184 | 132 | 202 | 172 | |
| EPS in Rs | 6.14 | 6.95 | 9.18 | 9.07 | 6.85 | 7.80 | 7.04 | 7.98 | 7.85 | 9.40 | 6.76 | 10.31 | 8.80 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
4 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.99% · closed higher next day 17 of last 57
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25† | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 7 Nov '23◦ | 5 Feb '24◦ | 9 May '24◦ | 8 Aug '24◦ | 7 Nov '24◦ | 3 Feb '25◦ | 6 May '25 | 5 Aug '25◦ | 4 Nov '25 | 5 Feb '26 | 15 May '26 | 4 Aug '26 |
| Earnings day | −0.97% | +2.15% | −2.57% | −6.89% | −3.86% | −2.88% | +1.13% | +0.18% | +3.95% | +1.52% | −0.20% | +0.45% |
| +1 day | −0.78% | +1.23% | −4.80% | −8.50% | −4.43% | −2.06% | +1.73% | +0.41% | −0.96% | −0.09% | −7.80% | +1.55% |
| +5 days | +0.65% | +2.95% | −4.14% | −11.78% | −5.12% | −4.35% | +2.35% | −0.40% | −0.82% | −1.06% | −3.82% | +4.11% |
| +15 days | +1.51% | +8.83% | −7.81% | −11.87% | +1.80% | −12.73% | +11.52% | −1.01% | −1.02% | −8.61% | −5.12% | −0.33% |
| +30 days | +4.49% | −2.04% | −9.87% | −4.02% | −4.12% | −8.00% | +8.12% | +1.32% | −8.34% | −15.16% | +4.72% | +2.43% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 12 Per Share | 12.00 | 29 Jul '26 | 29 Jul '26 |
Shareholding
as of Sep 202669.87%Promoter
Promoters69.87%
FIIs4.55%0.38
DIIs15.44%0.49
Public10.16%0.16
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,761.00 | 33.45 | 4,22,523 | 0.91% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,664.00 | 86.11 | 2,56,549 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,580.00 | 80.24 | 1,74,208 | 0.83% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,244.00 | 90.49 | 1,21,246 | 0.09% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,184.40 | 24.27 | 1,18,144 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,345.00 | 40.10 | 1,12,265 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,358.00 | 35.33 | 1,09,709 | 0.96% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Alembic Pharma | ₹794.85 | 20.94 | 15,624 | 1.51% | 172 | +12.11% | 2,150 | +25.66% | 12.64% |
| Median: 159 Co. | ₹439.10 | 34.49 | 1,934 | 0.08% | 14 | +22.88% | 170 | +18.91% | 15.11% |
Filings
Annual reports15
Concall transcripts65
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024PPTMay 2024TranscriptFeb 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - Alembic Pharmaceuticals will hold a Q2 FY27 results conference call on 4 November 2026 at 4:00 PM IST.Board Meeting Intimation for Considering Unaudited Financial Results For The Quarter And Half Year Ended 30Th September, 2026. 28 Oct - Board meeting on 4 November 2026 to approve Q2 and half-year FY2026 unaudited results.Announcement under Regulation 30 (LODR)-Newspaper Publication 28 OctAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 27 Oct - Alembic received USFDA final approval on 27 Oct 2026 for Valganciclovir oral solution 50 mg/mL.Intimation Under Regulation 30 Of SEBI LODR Regulations, 2015 19 Oct - Alembic Global Holding incorporated UAE subsidiary Alvesta Pharmaceuticals FZCO on 1 September 2026.